Prescription of LCZ696 in 1442 patients with Heart Failure with reduced Ejection Fraction included in the Multicenter French Survey OFICSEL

Background In paradigm-HF study, LCZ696 was superior to angiotensin converting enzyme inhibitors (ACEI) and reduced mortality in heart failure with reduced ejection fraction (HFrEF) patients. LCZ696 is now recommended in symptomatic patients with HFrEF despite optimal treatment with beta-blockers, ACEI and mineralocorticoid receptor antagonists (MRA). Purpose To evaluate LCZ696 prescription in real-life in and outpatients. Methods Prospective enrolment during 6 months in 2017. Data collection included demographic, burden, clinical, biological, echocardiography and treatment characteristics. Results A total of 1442 patients with left-ventricular ejection fraction (LVEF)  P P  = 0.016). NYHA status was better ( P P P  = 0.003) in LCZ696 patients. Patients treated by LCZ696 were more likely to be outpatients ( P Conclusion Almost one in four patients with LVEF